OSAKA -- Japanese biotech company Takara Bio will ramp up investment in its contract drug manufacturing business and build a new COVID vaccine plant to expand production capacity at its headquarters in Kusatsu, Shiga prefecture.
Under the plan, the biotech company hopes to produce 73 million doses of COVID vaccines in fiscal 2027, making it one of the largest contract vaccine manufacturers in Japan.
